BioCentury
ARTICLE | Company News

Management tracks

June 9, 2017 11:37 PM UTC

The board of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) has recommended election of four new directors at its annual shareholder meeting on July 13. They are Murray Goldberg, a former SVP and CFO at Regeneron Pharmaceuticals Inc. (NASDAQ:REGN); Roberto Mignone, the founding managing partner at Bridger Management; Perry Nisen, CEO and executive chair at Sanford Burnham Prebys Medical Discovery Institute; and Nechemia Peres, co-founding managing general partner at Pitango Venture Capital. Teva expects to fill positions vacated by Roger Abravanel, who intends to resign at the annual meeting; Joseph Nitzani and Ory Slonim, who will not seek re-election; and Kite Pharma Inc. (NASDAQ:KITE) Chairman, President and CEO Arie Belldegrun, who resigned from Teva's board in January. Kite is seeking a new CEO.

Neurology and pain company Braeburn Pharmaceuticals Inc. (Princeton, N.J.) named Michael Derkacz president and CEO. He was SVP and head of the global CNS and pain therapeutic areas at Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA). He succeeds Behshad Sheldon, who will continue to advise Braeburn...